Twist Bioscience Delivers Strong Q2 Results, Exceeding Market Expectations
In its recently reported second quarter financial results conference call, Twist Bioscience demonstrated another strong performance, extending its track record of consistent execution with 13 consecutive quarters of sequential revenue growth.
The company's CEO and Co-founder, Dr. Emily Leproust, highlighted the success of their semiconductor-based DNA synthesis platform, which provides a structural advantage in cost, scale, and speed that feeds into every product and service offered by Twist. This platform enables a highly efficient New Product Introduction engine, allowing the company to rapidly translate customer demand into scalable offerings and continuously expand its portfolio.
Twist's core technology advantage has driven sustained revenue growth, with total revenue reaching $110.7 million, up more than 19% year-over-year in Q2 2026. DNA synthesis and protein solutions grew 28%, powered by continued strength in AI-enabled drug discovery, while NGS applications grew 12% year-over-year and 9% sequentially.
The company's strategic investments have driven continued return on investment, with gross margin exceeding 50%. Dr. Leproust noted that Twist remains firmly on track to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
A notable highlight from Q2 was the announcement by Amazon Web Services (AWS) of Twist as a wet lab partner for its AI-powered drug discovery application, Amazon Bio Discovery. This validation of Twist's DNA synthesis, protein solutions, and biologics capabilities is an exciting development for the company.
Twist has been working closely with the AWS team to provide wet lab services for the scientific launch partners, including Memorial Sloan Kettering Cancer Center and the Gray Lab at Johns Hopkins University. The objective of researchers using Amazon Bio Discovery is to deploy AI models to design and optimize antibody candidates faster, and Twist aims to support them with products and services that accelerate this pathway.
As the company continues to innovate and expand its portfolio, it remains well-positioned to capitalize on emerging trends in life sciences. Dr. Leproust noted that the growth of AI-enabled drug discovery complements the company's work with customers pursuing traditional drug discovery, which remains a robust area of their business.
